JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?
60-Word AI Digest
JM Financial retained Buy ratings on Dr Reddy’s Laboratories and Aurobindo Pharma, seeing up to 28% upside over the next 12 months. The brokerage expects stronger earnings growth, business diversification and new product launches to support both drugmakers.
Key Takeaways
- JM Financial retained Buy ratings on Dr Reddy’s Laboratories and Aurobindo Pharma, seeing up to 28% upside over the next 12 months.
- The brokerage expects stronger earnings growth, business diversification and new product launches to support both drugmakers.
- Full details and original dispatch available below.
JM Financial retained Buy ratings on Dr Reddy’s Laboratories and Aurobindo Pharma, seeing up to 28% upside over the next 12 months. The brokerage expects stronger earnings growth, business diversification and new product launches to support both drugmakers.
Original Publisher Attribution
This summary was curated from Economic Times.